Yun-Ting Wang

Title: Innovations of Yun-Ting Wang in Anti-Angiogenesis

Introduction

Yun-Ting Wang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of anti-angiogenesis fusion proteins. With a total of 3 patents, his work is poised to impact therapeutic approaches for diseases associated with angiogenesis.

Latest Patents

One of his latest patents is titled "Anti-angiogenesis fusion protein and uses thereof." This invention provides a bi-functional fusion protein, represented as (AT)a-Fc-(VT)b, which simultaneously targets vascular endothelial growth factor (VEGF) and angiopoietins (ANGs). In this formula, AT serves as an ANG binding motif, while VT acts as a VEGF binding motif. The fragment crystallizable region (Fc) is derived from the N-terminal of Immunoglobulin G (IgG), with each of a and b being integers ranging from 1 to 10. The bi-functional fusion proteins consist of two or more domains of human proteins and are composed entirely of human sequences, making them expectedly non-immunogenic. This innovation holds potential for therapeutic applications in targeting diseases associated with angiogenesis.

Career Highlights

Yun-Ting Wang is currently associated with Trican Biotechnology Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to creating innovative solutions in the field of biotechnology.

Collaborations

He collaborates with esteemed colleagues such as Li-Tsen Lin and Jiun-Shyang Leou, contributing to a dynamic research environment that fosters innovation.

Conclusion

Yun-Ting Wang's contributions to the field of biotechnology, particularly through his patents on anti-angiogenesis fusion proteins, highlight his role as a significant inventor. His work not only showcases his innovative spirit but also promises to advance therapeutic strategies for angiogenesis-related diseases.